Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$805.50 USD

805.50
2,196,548

-0.64 (-0.08%)

Updated Nov 5, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal

Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.

CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study

CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

Lilly (LLY) to Acquire Prevail Therapeutics for Gene Therapies

Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.

Company News for Dec 16, 2020

Companies In The News Are: CHWY, AAPL, LLY, BIDU.

Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $160.04, moving -0.6% from the previous trading session.

Benjamin Rains headshot

3 Large-Cap Dividend Stocks to Buy and Hold Before 2021

Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

Company News for Dec 10, 2020

Companies In The News Are: UNFI,CATM,FEYE,LLY

Eli Lilly (LLY) Soars: Stock Adds 5.8% in Session

Eli Lilly (LLY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test

Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.

Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab

The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US

With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).

AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure

AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.

Ritujay Ghosh headshot

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US

RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

Sheraz Mian headshot

Top Stock Reports for NVIDIA, Pfizer & Abbott

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Pfizer (PFE) and Abbott Laboratories (ABT).

Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA

Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

Should Value Investors Choose Eli Lilly and Co (LLY) Stock?

Let's see if Eli Lilly and Co (LLY) stock is a good choice for value-oriented investors right now from multiple angles.